• To provide information concerning the immunogenicity of the 2005-2006 formulation of the inactivated, split-virion influenza vaccine Fluzone. [ Time Frame: 42 Days post-vaccination ] [ Designated as safety issue: No ]
  

Inclusion Criteria:

• Participant is aged >=6 months (24 weeks) to < 36 months (3rd birthday).
• Participant is considered to be in good health on the basis of reported medical history and limited physical examination.
• Participant is available for the duration of the study.
• Parent/legal acceptable representative is willing and able to provide informed consent.
• Parent/legal acceptable representative is willing and able to meet protocol requirements.
• Born at full term of pregnancy (>=37 weeks) with a birth weight >=2.5 kg.

Exclusion Criteria:

• Reported allergy to egg proteins, chicken proteins, or any other constituent of the vaccine.
• Documented history of influenza infection.
• An acute illness with or without fever (temperature >=100.4 °F rectal) in the 72 hours preceding enrollment in the trial (Enrollment may be deferred; see Section 5.3.5 of the protocol).
• Clinically significant findings in vital signs or review of systems investigator judgment; defer or exclude).
• Participation in any other interventional clinical trial within 30 days prior to enrollment up to termination of the subject's participation in the study.
• Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth.
• Personal or immediate family history of congenital immune deficiency.
• Developmental delay, neurologic disorder, or seizure disorder.
• Chronic medical, congenital, or developmental disorder.
• Known HIV-positive mother.
• Prior history of Guillain-Barré syndrome.
• Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.